Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis.
J Comp Eff Res
; 6(6): 497-508, 2017 Sep.
Article
em En
| MEDLINE
| ID: mdl-28485619
ABSTRACT
AIM:
Describe hairy cell leukemia (HCL) treatment patterns using a large, nationally representative US database. PATIENTS &METHODS:
Adults newly diagnosed with HCL (1 January 2006 to 30 June 2014) with continuous health plan enrollment ≥180 days pre- and 90 days post-diagnosis were identified from the QuintilesIMS PharMetrics Plus Health Plan Claims Database. Treatment patterns by line of therapy were assessed over the variable follow-up.RESULTS:
Among 749 HCL patients (77.4% male; mean age 55.6; mean 32.3 months follow-up), only 37.7% initiated first-line therapy during the available follow-up in a mean of 4.4 months following diagnosis; the majority (75.5%) received cladribine (mean duration 7.3 days). Thirty-eight patients (5.1%) received second-line treatment.CONCLUSION:
Over 2.7 years follow-up, more than a third of patients initiated first-line therapy which appeared to provide a long-lasting response.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia de Células Pilosas
/
Antineoplásicos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article